These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 11055820)

  • 1. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
    Everts B; Währborg P; Hedner T
    Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs.
    Urban MK
    Orthopedics; 2000 Jul; 23(7 Suppl):S761-4. PubMed ID: 10914695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.
    Mazario J; Gaitan G; Herrero JF
    Neuropharmacology; 2001 Jun; 40(7):937-46. PubMed ID: 11378164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
    Linder JD; Mönkemüller KE; Davis JV; Wilcox CM
    South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
    Rioda WT; Nervetti A
    Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
    Nakamura H
    Nihon Yakurigaku Zasshi; 2001 Sep; 118(3):219-30. PubMed ID: 11577463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 inhibitors.
    Hawkey CJ
    Lancet; 1999 Jan; 353(9149):307-14. PubMed ID: 9929039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First and second generations of COX-2 selective inhibitors.
    de Leval X; Julémont F; Benoit V; Frederich M; Pirotte B; Dogné JM
    Mini Rev Med Chem; 2004 Aug; 4(6):597-601. PubMed ID: 15279593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.
    Habeeb AG; Praveen Rao PN; Knaus EE
    J Med Chem; 2001 Aug; 44(18):3039-42. PubMed ID: 11520213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B; Brune K
    Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
    Tindall E
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
    Blain H; Jouzeau JY; Netter P; Jeandel C
    Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.